Scarica l'app Stockscreener
203.04
3.02%
5.96
Dopo l'orario di chiusura:
202.00
-1.04
-0.51%
Precedente Chiudi:
$197.08
Aprire:
$199.73
Volume 24 ore:
1.55M
Relative Volume:
1.15
Capitalizzazione di mercato:
$28.31B
Reddito:
$2.12B
Utile/perdita netta:
$-309.19M
Rapporto P/E:
-88.89
EPS:
-2.2841
Flusso di cassa netto:
$93.57M
1 W Prestazione:
-12.16%
1M Prestazione:
-18.37%
6M Prestazione:
+46.99%
1 anno Prestazione:
+15.93%
Intervallo 1D:
$194.02
$203.68
Intervallo di 1 settimana:
$194.02
$236.58
Portata 52W:
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
203.04 | 27.48B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
542.83 | 203.77B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.61 | 152.51B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
644.61 | 51.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
129.58 | 36.75B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
187.49 | 30.69B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Citigroup | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-27 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Ripresa | Wells Fargo | Equal Weight |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
Is Natera (NTRA) Quietly Redefining Its Moat With Multi-Front Cell-Free DNA Expansion? - simplywall.st
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes - Yahoo Finance
This brand-new Peninsula building sat vacant for a year. Now it's landed two big tenants - The Business Journals
News | Genetic testing firm inks deal at Silicon Valley life science campus - CoStar
Natera CEO sells $20.7 million in NTRA stock By Investing.com - Investing.com South Africa
Natera sec. and chief legal officer sells $307k in stock - Investing.com UK
Natera director Sheena Jonathan sells $100k in stock By Investing.com - Investing.com Australia
Natera sec. and chief legal officer sells $307k in stock By Investing.com - Investing.com South Africa
Natera CEO sells $20.7 million in NTRA stock - Investing.com
Natera Inc. president Fesko sells $830k in stock By Investing.com - Investing.com India
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock By Investing.com - Investing.com UK
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock - Investing.com
Natera director Sheena Jonathan sells $100k in stock - Investing.com
Oversold Conditions For Natera (NTRA) - Nasdaq
Natera Inc (NTRA) Stock Price Down 7.82% on Feb 4 - GuruFocus
Principal Financial Group Inc. Has $69.11 Million Stake in Natera, Inc. $NTRA - MarketBeat
National Pension Service Invests $1.49 Million in Natera, Inc. $NTRA - MarketBeat
Trading Systems Reacting to (NTRA) Volatility - Stock Traders Daily
Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test - The Globe and Mail
Exploring US High Growth Tech Stocks This February 2026 - simplywall.st
Natera submits FDA approval for bladder cancer test By Investing.com - Investing.com Nigeria
Natera Files FDA PMA for Signatera CDx in Muscle-Invasive Bladder Cancer - Oncodaily
Natera, Inc. (NTRA) Stock Analysis: Potential Growth Amidst Strong Analyst Confidence - DirectorsTalk Interviews
FDA premarket approval sought for Signatera CDx test in MIBC - Urology Times
Natera Submits Signatera™ CDx PMA to FDA - MEXC
Natera Submits Premarket Approval Application for Molecular Residual Disease Test Signatera CDx - marketscreener.com
NTRA Submits PMA to FDA for Bladder Cancer Detection Innovation - GuruFocus
Natera submits Signatera(TM) CDx PMA to FDA - marketscreener.com
Natera submits FDA approval for bladder cancer test - Investing.com
Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Inflation Data: Is now the right time to enter Natera IncQuarterly Portfolio Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
Natera, Inc. $NTRA Shares Purchased by New York State Common Retirement Fund - MarketBeat
$8.25M Natera prenatal screening class action settlement - Class Action Lawsuits
Short Interest in Natera, Inc. (NASDAQ:NTRA) Declines By 27.2% - MarketBeat
A Look At The Fair Value Of Natera, Inc. (NASDAQ:NTRA) - Yahoo Finance
Natera, Inc. $NTRA Shares Purchased by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 2,413 Shares of Stock - MarketBeat
Michael Burkes Brophy Sells 1,867 Shares of Natera (NASDAQ:NTRA) Stock - MarketBeat
Natera (NASDAQ:NTRA) CFO Sells $188,575.52 in Stock - MarketBeat
Natera (NASDAQ:NTRA) CEO Sells $866,983.68 in Stock - MarketBeat
Natera CFO Brophy sells $1.19 million in shares By Investing.com - Investing.com South Africa
Natera CEO sells $1.4m in NTRA stock By Investing.com - Investing.com Nigeria
Natera CEO sells $1.4m in NTRA stock - Investing.com
Natera (NASDAQ:NTRA) Insider Sells $285,192.00 in Stock - MarketBeat
Natera (NASDAQ:NTRA) Insider John Fesko Sells 928 Shares - MarketBeat
Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 784 Shares of Stock - MarketBeat
Natera co-founder Sheena Jonathan sells $115k in stock By Investing.com - Investing.com South Africa
Natera president sells $528k in NTRA stock By Investing.com - Investing.com South Africa
Natera president sells $528k in NTRA stock - Investing.com
Natera co-founder Sheena Jonathan sells $115k in stock - Investing.com
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
3.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):